Physician profile
Deborah Cross
NPI 1447483193
$1,084.79
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.49 · 2022: $423 · 2023: $300 · 2024: $158 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.30 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.85 | 2022-2023 | |
| Novo Nordisk INC | $114.09 | 2021-2025 | Ozempic |
| Vanda Pharmaceuticals INC. | $108.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $91.63 | 2022-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $79.80 | 2022-2025 | Breztri |
| Braeburn INC. | $58.77 | 2023-2024 | Brixadi |
| Novartis Pharmaceuticals Corporation | $44.55 | 2022-2023 | |
| Alkermes, INC. | $38.73 | 2022-2025 | Vivitrol |
| Indivior INC. | $33.84 | 2023-2024 | Sublocade |
| Biohaven Pharmaceutical Holding Company LTD. | $24.03 | 2022 | |
| Abbott Laboratories | $22.21 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $16.33 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.